IRVINE, Calif., Dec. 7, 2005 (PRIMEZONE) -- "In a biotechnology industry racing awkwardly to prepare for the juggernaut of aging baby boomers, there is a chorus of wild claims, projections and promises," stated SmallCap Sentinel analyst, D.R. Clark. "But astute investors will survey the biotech landscape for companies garnering patents and FDA approvals. As laypeople we can't know the essence of their science or vet the veracity of their claims but we can look to patent and FDA approval as a means to separate snake oil from solution."
"Callisto Pharmaceutical's (AMEX:KAL) recent announcements confirming two major drugs in clinical trials is pretty unusual," Clark added. "This is the second announcement of late noting patent and trial progression," Clark added. "For investors, this should signal some separation for Callisto from the cure-all crowd. These are real events."
Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at: www.SmallCapSentinel.com.
The report will address issues regarding emergent biotechnology potentially affecting drug makers such as Abbott Laboratories (NYSE:ABT), AstraZeneca PLC ADS (NYSE:AZN), and GlaxoSmithKline PLC (NYSE:GSK).
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.